Protalix BioTherapeutics Inc. (PLX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Protalix BioTherapeutics Inc. (NYSE: PLX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.59 (-0.77% 1D, market cap $210.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLX ranks #901 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PLX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 48.8%, and ROIC of -13.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and ARTV (Artiva Biotherapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per PLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001006281), Protalix BioTherapeutics Inc. generated $52.7M in revenue (-1.2% YoY), -$6.6M in net income, and -$13.6M in free cash flow against $82.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±8.1% realized swing band)
FRED Regime × Technicals: 61% of 52W Range • RSI-14 at 47.3 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PLX currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.64) and Max Pain ($2.72) forces dealer call-delta covering toward $3.35.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Protalix BioTherapeutics Inc. (PLX) slipped -0.77% to $2.59, trading at 61% of its 52-week range ($1.65 – $3.19). Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unme
Fed officials are signaling a pause on interest rate hikes in October, with the possibility of another move in December. That kind of limbo often encourages investors to look at smaller, overlooked companies with cleaner
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PLX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PLX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Protalix BioTherapeutics Inc. (PLX) ranks #901 by composite RQD confidence (28/100, grade E) and #568 by equity capitalization ($210.3M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with PLX at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PLX
ACTIVE
Protalix BioTherapeutics Inc. | E | 28/100 | — | 48.8% | -13.0% | -0.77% | $210.3M | Benchmark Subject |
| PALI Palisade Bio Inc. | D- | 43/100 | — | — | -35.0% | -2.52% | $207.4M | /pali-vs-plx → |
| ARTV Artiva Biotherapeutics Inc. | D- | 39/100 | — | — | -35.0% | -0.95% | $206.8M | /artv-vs-plx → |
| DTIL Precision BioSciences Inc. | E | 24/100 | — | — | -35.0% | -5.11% | $205.4M | /dtil-vs-plx → |
| CGEN Compugen Ltd. | B+ | 78/100 | 5.5x | 87.3% | 85.0% | -2.94% | $193.0M | /cgen-vs-plx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Protalix BioTherapeutics Inc. (PLX) reported GAAP revenue of $52.7M (-1.2% vs. FY2024 revenue of $53.4M , and -19.5% cumulative change since FY2023) , GAAP net income of -$6.6M, operating cash flow of -$12.0M, and free cash flow of -$13.6M (-284.4% YoY). On the balance sheet, PLX closed FY2025 with $82.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $52.7M | -$6.6M | -$12.0M | -$13.6M | $82.3M | — |
| FY2024 (FY) | 2024-12-31 | $53.4M | $2.9M | $8.7M | $7.4M | $73.4M | — |
| FY2023 (FY) | 2023-12-31 | $65.5M | $8.3M | -$1.3M | -$1.3M | — | — |
As of 2026-11-02, Protalix BioTherapeutics Inc. (NYSE: PLX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.59 (-0.77% 1D, market cap $210.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLX ranks #901 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PLX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 48.8%, and ROIC of -13.0%. By comparison, PALI (Palisade Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $207.4M) and ARTV (Artiva Biotherapeutics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $206.8M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).
Per PLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001006281), Protalix BioTherapeutics Inc. generated $52.7M in revenue (-1.2% YoY), -$6.6M in net income, and -$13.6M in free cash flow against $82.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PLX last traded at $2.59 (-0.77% on volume of 249,290 shares), positioning the stock -1.89% below its 50-day simple moving average ($2.64) and +7.47% above its 200-day simple moving average ($2.41). Across its 52-week range of $1.65 to $3.19, PLX sits at the 61.0% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($2.38 to $2.80).
Why PLX Stock slipped -0.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).